WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597866
CAS#: 103221-88-1
Description: BW-A 575C is an ACE inhibitor.
Hodoodo Cat#: H597866
Name: BW-A 575C
CAS#: 103221-88-1
Chemical Formula: C29H43N5O8
Exact Mass: 589.31
Molecular Weight: 589.690
Elemental Analysis: C, 59.07; H, 7.35; N, 11.88; O, 21.70
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BW-A 575C; BW-B385C; BWB385C; BW B385C;
IUPAC/Chemical Name: (1-carboxy-5-(4-(2-hydroxy-3-(isopropylamino)propoxy)-1H-indole-2-carboxamido)pentyl)alanyl-L-proline
InChi Key: XCLLRLKRCYZTES-PBKHYBTFSA-N
InChi Code: InChI=1S/C29H43N5O8/c1-17(2)31-15-19(35)16-42-25-11-6-9-21-20(25)14-23(33-21)26(36)30-12-5-4-8-22(28(38)39)32-18(3)27(37)34-13-7-10-24(34)29(40)41/h6,9,11,14,17-19,22,24,31-33,35H,4-5,7-8,10,12-13,15-16H2,1-3H3,(H,30,36)(H,38,39)(H,40,41)/t18?,19?,22?,24-/m0/s1
SMILES Code: O=C(O)[C@H]1N(C(C(C)NC(C(O)=O)CCCCNC(C(N2)=CC3=C2C=CC=C3OCC(O)CNC(C)C)=O)=O)CCC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 589.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Cambridge D, Allan G, Hardy GW, Follenfant MJ, Ford A, Oliver PL. BW A575C: pharmacological profile in vivo of a novel angiotensin converting enzyme inhibitor and beta-blocker. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S64-8. PubMed PMID: 2454371.
2: Cambridge D, Whiting MV, Allan G. Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties. Br J Pharmacol. 1988 Jan;93(1):165-75. PubMed PMID: 2894874; PubMed Central PMCID: PMC1853785.
3: Cambridge D, Whiting MV, Butterfield LJ, Allan G. The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs. Br J Pharmacol. 1992 Jun;106(2):342-7. PubMed PMID: 1356560; PubMed Central PMCID: PMC1907514.